Skip to main content

Drug Interactions between cilastatin / imipenem / relebactam and probenecid

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

probenecid imipenem

Applies to: probenecid and cilastatin / imipenem / relebactam

Coadministration with probenecid may increase the plasma concentrations of carbapenem antibiotics. The mechanism involves competitive inhibition of carbapenem renal excretion via active tubular secretion. Significant pharmacokinetic alterations have been reported for some carbapenems such as doripenem and meropenem, but not for others like ertapenem and imipenem. According to the product labeling for ertapenem, coadministration with probenecid (500 mg orally every 6 hours) resulted in a 25% increase in ertapenem systemic exposure (AUC) and a 20% and 35% reduction in plasma and renal clearance, respectively. The half-life increased from 4.0 to 4.8 hours. Similar changes have been reported for imipenem. Because of the small effect on half-life, the coadministration with probenecid to extend the half-life of ertapenem or imipenem is not recommended.

References (4)
  1. (2001) "Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals
  2. (2001) "Product Information. Invanz (ertapenem)." Merck & Co., Inc
  3. (2003) "Product Information. Primaxin (imipenem-cilastatin)." Merck & Co., Inc
  4. (2007) "Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer